{"id":5310,"date":"2024-04-07T23:19:51","date_gmt":"2024-04-07T15:19:51","guid":{"rendered":"https:\/\/flcube.com\/?p=5310"},"modified":"2024-10-13T18:52:01","modified_gmt":"2024-10-13T10:52:01","slug":"ascletis-pharma-halts-asc42-phase-ii-study-in-primary-biliary-cholangitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5310","title":{"rendered":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis"},"content":{"rendered":"\n

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV).<\/p>\n\n\n\n

The Phase II trial for ASC42 in PBC involved three active treatment groups (5mg, 10mg, and 15mg once daily) alongside a placebo control group. Results from the 12-week efficacy and safety assessment indicated that ASC42 lacks a competitive edge compared to emerging PBC therapies currently in development and registration.<\/p>\n\n\n\n

As of December 31, 2023, Ascletis reported cash and cash equivalents of approximately RMB 2.3 billion. The decision to discontinue ASC42 is part of a strategic initiative to optimize the company’s R&D pipeline and conserve cash. Funds saved from this decision will be redirected to advancing clinical studies for the thyroid hormone receptor \u03b2 (THR) \u03b2 agonist ASC41 and the fatty acid synthase (FASN) inhibitor ASC40 (denifanstat) in NASH and other indications.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[189,17,980],"class_list":["post-5310","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascletis-pharma","tag-clinical-trial-results","tag-hkg-1672"],"yoast_head":"\nAscletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5310\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5310\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-07T15:19:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:52:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis\",\"datePublished\":\"2024-04-07T15:19:51+00:00\",\"dateModified\":\"2024-10-13T10:52:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310\"},\"wordCount\":183,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"Clinical trial results\",\"HKG: 1672\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5310#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5310\",\"name\":\"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-07T15:19:51+00:00\",\"dateModified\":\"2024-10-13T10:52:01+00:00\",\"description\":\"China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5310\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5310#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis - Insight, China's Pharmaceutical Industry","description":"China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5310","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5310","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-07T15:19:51+00:00","article_modified_time":"2024-10-13T10:52:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5310#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5310"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis","datePublished":"2024-04-07T15:19:51+00:00","dateModified":"2024-10-13T10:52:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5310"},"wordCount":183,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","Clinical trial results","HKG: 1672"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5310#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5310","url":"https:\/\/flcube.com\/?p=5310","name":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-07T15:19:51+00:00","dateModified":"2024-10-13T10:52:01+00:00","description":"China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II clinical study for ASC42 in primary biliary cholangitis (PBC) following a comprehensive data analysis. The farnesoid X receptor (FXR) agonist will also see the cancellation of studies in non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5310#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5310"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5310#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5310"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5310\/revisions"}],"predecessor-version":[{"id":6026,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5310\/revisions\/6026"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}